Abstract: Embodiments of the invention relate to aluminum alloy conductor composite reinforced for high voltage overhead power lines and associated methods of use and manufacture. In one embodiment, a transmission cable can be provided. The transmission cable can include a core including at least one of: a composite core, a plurality of fibers in a matrix of one or more materials, or a set of carbon fibers embedded in an epoxy matrix; and a plurality of wires wrapped around the core, wherein the wires comprise at least one of the following: aluminum 6201 T83 alloy, aluminum 6201 T81 alloy, aluminum 1350-H19 alloy, or a heat resistant aluminum-zirconium alloy; wherein the transmission cable has a low sag characteristic.

Abstract: The present invention provides a method of treating sickle cell anemia comprising the step of administering to an individual in need of said treatment a therapeutically acceptable dose of reducing agent. In yet another embodiment of the present invention, there is provided a method of pharmacologically correcting a post-translational modification of the .beta.-actin protein in sickled erythrocytes, comprising the step of contacting said sickled erythrocytes with a pharmacologically effective dose of a reducing agent. In still yet another embodiment of the present invention, there is provided a method of identifying a drug for use in treating sickle cell anemia. Any drug which hastens the HDSS Core Skeleton dissociation rate is tested by the in vitro ternary complex dissociation assay to test whether its effect is on HDSS beta-actin. Furthermore, drugs can be tested by the oxygenation-deoxygenation cycling assay for its ability to block ISC formation in vitro.